Bayesian Methods for the Analysis of Early-Phase Oncology Basket Trials
  with Information Borrowing across Cancer Types by Jin, Jin et al.
Bayesian Methods for the Analysis of Early-Phase Oncology Basket
Trials with Information Borrowing across Cancer Types
Jin Jin1∗, Marie-Karelle Riviere2, Xiaodong Luo3, Yingwen Dong4
1Department of Biostatistics, Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD, USA
2Department of Biostatistics and Programming, Research and Development,
Sanofi, Chilly-Mazarin, France.
3Department of Biostatistics and Programming,
Sanofi, Bridgewater, NJ, U.S.
4Department of Biostatistics and Programming Oncology,
Sanofi, Cambridge, MA, U.S.
Abstract
Research in oncology has changed the focus from histological properties of tumors in a specific
organ to a specific genomic aberration potentially shared by multiple cancer types. This motivates the
basket trial, which assesses the efficacy of treatment simultaneously on multiple cancer types that have
a common aberration. Although the assumption of homogeneous treatment effects seems reasonable
given the shared aberration, in reality, the treatment effect may vary by cancer type, and potentially
only a subgroup of the cancer types respond to the treatment. Various approaches have been proposed
to increase the trial power by borrowing information across cancer types, which, however, tend to inflate
the type I error rate. In this paper, we review some representative Bayesian information borrowing
methods for the analysis of early-phase basket trials. We then propose a novel method called the
Bayesian hierarchical model with a correlated prior (CBHM), which conducts more flexible borrowing
across cancer types according to sample similarity. We did simulation studies to compare CBHM
with independent analysis and three information borrowing approaches: the conventional Bayesian
hierarchical model, the EXNEX approach and Liu’s two-stage approach. Simulation results show that
all information borrowing approaches substantially improve the power of independent analysis if a
large proportion of the cancer types truly respond to the treatment. Our proposed CBHM approach
shows an advantage over the existing information borrowing approaches, with a power similar to that
of EXNEX or Liu’s approach, but the potential to provide substantially better control of type I error
rate.
Keywords— Basket trials Bayesian hierarchical models Between-indication similarity Early-phase oncology
study Information borrowing across cancer types
1 Introduction
Traditional oncology therapeutic research and drug development have mainly focused on the histological properties
of tumors in each specific organ. Now with enhanced technology in biomarker development and genomic medicine,
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the focus has shifted from conventional chemotherapy to targeted therapy on a specific genomic or molecular
aberration, which can potentially be shared by multiple histological cancer types in different organs. Under this
new paradigm, a recently emerged type of trial called basket trial has received increasing attention. A basket
trial enrolls patients with multiple histological cancer types (indications) that share the same genomic or molecular
aberration, and assesses the efficacy of a particular targeted therapy simultaneously on all of the enrolled indications.
Previous research has shown that basket trials tend to require fewer patients and shorter trial duration to identify
indications that respond to the treatment; in addition, it has the advantage of allowing patients with certain rare
cancer types to be eligible to participate in clinical trials (Redig and Jänne, 2015; Chu and Yuan, 2018).
Typically, in the early, exploratory phase of oncology basket trials, only a small number of patients are enrolled
for each indication, thus assessing the treatment effect on each indication independently is inefficient with low
statistical power. In a basket trial, all indications share the same genetic or genomic aberration, leading to a prior
guess of homogeneous treatment effects. Based on this exchangeability (EX) assumption, the idea of borrowing
information across indications was introduced by the use of Bayesian hierarchical model (BHM) to improve trial
efficiency, where the treatment effects are assumed to be exchangeable and centering around a common mean (Thall
et al., 2013; Berry et al., 2013). In reality, however, the EX assumption is often violated, and it is common that only
a subset of the indications are sensitive (i.e. the patients respond positively) to the treatment. For example, the
MyPathway study shows that the response rate to trastuzumab plus pertuzumab differs greatly between several
HER2-amplified/overexpressing tumor types (Hainsworth et al., 2018). In this case, BHM tends to over-shrink
treatment effects toward the common mean, which can lead to highly inflated type I error rate for the insensitive
indications (Freidlin and Korn, 2013).
Recently, various information borrowing approaches have been proposed for early-phase basket trials to improve
the power of independent analysis and, at the same time, provide better type I error control than BHM. However,
no formal investigation has been conducted on the relative performance of these existing approaches. In this paper,
we discuss two recently published approaches. One is the exchangeability-nonexchangeability (EXNEX) method
(Neuenschwander et al., 2016), which is a robust extension of the conventional BHM that assumes that each
indication is either exchangeable (EX) with some indications or nonexchangeable (NEX) with any other indication,
i.e. an outlier. The other is Liu’s two-path method, which introduces an interim homogeneity test, and only
conducts information borrowing when there is not enough evidence to reject the homogeneity hypothesis (Liu et
al., 2017). This homogeneity test is introduced for better type I error control. However, the doubt raises regarding
the necessity of the test because it introduces additional tuning parameters and complicates the trial design. In
addition, the evidence for heterogeneity does not necessarily indicate that all indications are heterogeneous and
should be analyzed independently. These motivated us to develop a more flexible information borrowing approach,
which takes into account the potentially different similarity levels between indications. In addition to EXNEX and
Liu’s approach, there are other existing information borrowing approaches, such as BLAST (Chu and Yuan, 2018),
which requires longitudinal biomarker measurements for promising performance, but the measurements are not
always available in early-phase basket trials. Other approaches include Cunanan’s two-path approach (Cunanan
et al., 2017), Bayesian response-adaptive approach (Ventz et al., 2017), Chen’s approach (Chen et al., 2016) and
GSED (Magnusson and Turnbull, 2013), which either have similar ideas as EXNEX or Liu’s approach, or show
limited improvement in trial efficiency compared to independent analysis, or come with trials designs that are too
complex for implementation, and therefore are not considered for further investigation.
In this paper, we first review several existing methods for the analysis of basket trials in early-phase oncology
studies, including the independent analysis, BHM, EXNEX and Liu’s approach. We then propose a novel approach
using a Bayesian hierarchical model with a correlated prior (CBHM), which conducts more flexible borrowing based
on the sample similarity between indications. CBHM introduces a correlation structure in the prior distribution
of the log odds parameters that is determined by the sample “distance” between indications. This encourages
information borrowing between the indications that appear to be homogeneous, and avoids excessive borrowing from
the outliers, aiming to provide better type I error control while still improving the power of independent analysis.
A two-stage trial design is proposed along with CBHM. We conducted simulation studies to investigate the relative
performance between the various approaches discussed. Simulation results show that when the proportion of the
sensitive indications is relatively large (e.g. > 3 out of 6), the information borrowing approaches (BHM, EXNEX,
Liu’s approach and CBHM) have substantially higher power than independent analysis. Our proposed CBHM
approach shows advantage over the existing information borrowing approaches, with a robust overall performance,
a power comparable to that of EXNEX or Liu’s approach depending on the data scenario, and the potential to
provide substantially better type I error control especially when the total number of indications and the proportion
of the sensitive indications are large. An additional feature of CBHM is that it comes with a detailed instruction
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for prior specification and trial design in a general setting, which is not provided by most existing methods and
ensures the applicability of CBHM in a wider range of basket trials.
The remainder of the paper is organized as follows. In Section 2, we briefly review several representative
methods for the analysis of early-phase basket trials, then introduce our CBHM approach. In Section 3, we present
simulation results to discuss the performance of the various approaches. Conclusions and discussion of future work
are summarized in Section 4.
2 Methods
Suppose that in an early-phase basket trial, a small number of patients with I cancer types that share the same
genomic or molecular aberration are enrolled. We denote the true response rate of the ith indication as pi. For
simple illustration, we set the standard of care (null) response rate to q0, and the target response rate to q1, for all
indications. Our objective is to test whether or not each indication responds positively to the treatment:
H0 : pi 6 q0, versus Ha : pi > q1, for i = 1, 2, . . . , I.
In Section 2.1, we introduce the two reference methods, the Bayesian independent approach and BHM. In Section
2.2, we give a brief overview of the two recently proposed information borrowing approaches, EXNEX and Liu’s
approach, whose performance we would like to investigate. We then introduce our proposed CBHM approach in
Section 2.3.
2.1 Reference methods
2.1.1 Independent analysis
Independent analysis is simple and widely used in clinical trials. Assume that the binary response of the jth
patient in the ith indication group is Yij , where Yij = 1 indicates positive response to the treatment and Yij = 0
indicates no positive response. Here we consider a Bayesian independent approach with a beta-binomial model,
where Yij
i.i.d.∼ Ber(pi), with Ber(p) denoting a Bernoulli distribution with probability p, and each pi is assumed to
have a flat prior, Beta(1, 1), where Beta(α, β) denotes the Beta distribution with shape paramters α and β. The
hypothesis testing procedure will be introduced in the trial process in Section 2.3.3.
2.1.2 Bayesian hierarchical model (BHM)
Thall et al. (2003) and Berry et al. (2013) discussed the use of Bayesian hierarchical model (BHM) to improve
the trial efficiency of basket trials by borrowing information across indications (Thall et al., 2013; Berry et al.,
2013). This conventional BHM assumes that the log odds parameters of all indications are exchangeable and center
around a common mean, specifically, {θi = log(pi/(1− pi)), i = 1, 2, . . . , I} follow a common prior, N(θ0, σ2). By
assuming common mean θ0 and variance σ2, BHM combines information from all indications.
2.2 Two recently published information borrowing approaches
2.2.1 EXNEX
Neuenschwander et al. (2016) proposed an EXNEX method, which robustifies the conventional BHM that has
a full EX assumption (Neuenschwander et al., 2016). EXNEX adopts a Bayesian hierarchical mixture model
that allows each log odds parameter θi = log(pi/(1 − pi)) to be either exchangeable with parameters of some
indications or nonexchangeable with any other parameter. This raises two possibility for each indication i: (1)
EX: θi|µ0, σ20 ∼ N(µ0, σ20) with probability pii and EX parameters µ0 and σ20 ; (2) NEX: θi|µi, σ2i ∼ N(µi, σ2i ), with
probability 1− pii and indication-specific parameters µi and σ2i .
2.2.2 Liu’s two-path approach
Liu et al. (2017) proposed to conduct an interim homogeneity test to decide the necessity of information borrowing
across indications (Liu et al, 2017). Figure 1 shows the flow chart of Liu’s approach. Specifically, at decision point
(a), a homogeneity test is conducted on {p1, p2, . . . , pI} using Cochran’s Q test. If the homogeneity hypothesis
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is rejected and it is concluded that at least one indication is different from others, then the trial proceeds to the
“heterogeneity path” using Simon’s two-stage design (Simon, 1989). But if there is not enough evidence to reject
homogeneity, the trial then proceeds to the “homogeneity path”: first, a futility analysis is conducted at decision
point (b) by calculating the Bayesian predictive power given pˆi,1 = ri,1/ni,1 (ni,j and ri,j denote the number of
patients and responders, respectively, for the ith indication in stage j). After assuming a Beta(0.5, 0.5) prior on pi,
ri,2 is simulated from its posterior distribution based on the beta-binomial model (ni,1+0.5, ri,1+0.5, ni,1). The final
response rate, pˆi = (ri,1 + ri,2)/(ni,1 + ni,2), and the Bayesian predictive power of (pˆi > p0) are then calculated. If
the predictive power is less than a threshold C, the enrollment will be stopped early, and the indication is concluded
to be insensitive to the treatment. In the end, a BHMM with two mixture components is applied to the final data:
Yij
i.i.d.∼ Ber(pi),
θi = log
pi
1− pi ,
θi = δiMi1 + (1− δi)Mi2,
δi ∼ Ber(pii), Mi1 ∼ N(µ1, σ21), Mi2 ∼ N(µ2, σ22),
where δi is the indicator for the mixture component the ith indication belongs to, with δi = 1 indicating the first
component and δi = 0 indicating the second, pii is the prior probability of δi = 1, Mij is the logit response rate
of the ith indication if the indication belongs to the jth component, µj and σ2j are the prior mean and variance
parameters, respectively, of Mij , i = 1, 2, . . . , I, j = 1, 2.
Figure 1: Flow chart of Liu’s two-path approach, pi denotes the response rate of the ith indication, and
q0 is the null response rate (Liu et al., 2017). The indications that are concluded to be homogeneous but
do not pass the predictive power evaluation at (b) are also included in the BHMM analysis.
2.3 Bayesian hierarchical model with a correlated prior (CBHM)
2.3.1 Model specification
The CBHM approach was motivated by the goal of borrowing more information between indications that are
possibly homogeneous, and less information from the indication that is likely an outlier. The basic idea is to
conduct flexible borrowing based on pairwise sample similarity of the indications, which can be described by the
pairwise sample correlations. We utilize the idea of modeling the spatial correlation between geostatistical locations:
imagine that the indications are different locations on a map, and dij , the distance between locations i and j, is
defined as the distance between the posterior distributions of their response rates. To induce information borrowing
based on sample similarity, we introduce correlated indication-specific effects, η = (η1, η2, . . . , ηI)T , on the vector
of log odds parameters, θ = (θ1, θ2, . . . , θI)T , and assume that θi = θ0 + ηi + i, with θ0 being the common mean,
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and  = (1, 2, . . . , I)T being a vector of independent random errors. The model setup for CBHM is then:
Yij
i.i.d.∼ Ber(pi),
θi = log
pi
1− pi ,
θi = θ0 + ηi + i,
η ∼MVN (0,σ2R(φ)), i i.i.d.∼ N(0, τ2), (1)
where R(φ) denotes the between-indication correlation matrix for θ, and the sample similarity between indications
i and j is reflected by its (i, j)-th entry, Rij(φ) = ρ(dij |φ), σ2 and τ2 denote the between- and within-indication
variance, respectively. Model (1) is developed for the basket trials with binary outcome. For a trial with continuous
outcome, the model can be modified by replacing the logit link function with a link function that transforms Yij
to be approximately normally distributed.
We now discuss the construction of the correlation matrix R(φ). In early-phase oncology trials, the endpoints
are often defined as the patients’ binary responses, in which case it is infeasible to calculate the commonly used
Pearson correlation between response rates. We instead define the correlation as a function of the sample “distance”:
the distance between the posterior distributions of the response rates. There are multiple choices regarding the
measure of distance between two probability distributions. One is the commonly used Kullback-Leibler (KL)
divergence, which measures the directed divergence from one distribution to another (Burnham and Anderson,
2001). We denote the data for the ith and jth indications as Di = {ni, ri} and Dj = {nj , rj}, respectively, where
ni and ri are the sample size and the number of responders, respectively. The KL divergence from the posterior
distribution of pj , which we denote as (pj |Dj), to the posterior distribution of pi, (pi|Di), is defined as:
DKL(f(pi|Di)||f(pj |Dj)) =
∫
f(p|Di) log f(p|Di)
f(p|Dj)dp,
where f(pi|Di) denotes the probability density function (pdf) of (pi|Di). Note that the KL divergence from (pj |Dj)
to (pi|Di) is not equal to the KL divergence from (pi|Di) to (pj |Dj). To define a symmetric distance measure, we
take the average of the two and define the KL distance between the ith and jth indications as:
dKLi,j =
1
2
(∫
f(p|Di) log f(p|Di)
f(p|Dj)dp+
∫
f(p|Dj) log f(p|Dj)
f(p|Di) dp
)
.
There are symmetric distance measures as well, such as the Hellinger (H) distance (Hellinger, 1909):
dHi,j =
√
1−
∫ √
f(p|Di)f(p|Dj)dp,
and the Bhattacharyya (B) distance (Kailath, 1967):
dBi,j = − log
{∫ √
f(p|Di)f(p|Dj)dp
}
.
In general, different distance measures vary by the smoothness and scale. Figure 2 shows the different behaviors of
KL, H and B distance. We can observe that H distance is the most smooth, which changes slowly as the difference
between sample response rates changes, and lies within [0, 1). KL distance is the least smooth with a much larger
differentiability and lies within [0,+∞). B distance is more smooth than KL distance and less smooth that H
distance, and has a support of [0,+∞).
Given distance dij , the sample correlation between the ith and jth indications is defined as a function of dij
with a set of correlation parameters, ζ. There are many choices for the correlation function, among which one of
the most widely used one is the matérn correlation function: ρ(dij |ζ) = 12ν−1Γ(ν)
(
2ν1/2dij
φ
)ν
Jν
(
2ν1/2dij
φ
)
, where
ζ = {φ, ν}, φ is the range parameter (larger φ indicates larger-scale correlation), ν is the smoothness parameter
(larger ν indicates smoother correlation), Γ(·) is the gamma function, and Jν(·) is the modified Bessel function of
the second kind with order ν (Stein, 2012). We consider two commonly used special cases of Matérn correlation:
exponential correlation (ν = 0.5) and squared exponential correlation (ν → ∞), where the former is defined as
e−φdij and the latter is defined as e−φd
2
ij . Figure 3 shows a comparison between the exponential and squared
exponential correlation functions under different values of φ. We can see that the squared exponential correlation is
more smooth, and compared to the exponential correlation, it induces higher correlation (i.e. stronger borrowing)
under small distance, and lower correlation (i.e. weaker borrowing) under large distance.
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Figure 2: B, H and KL distance between two indications given sample sizes n1 = n2 = 24, the number of
responders r1 = 10 and r2 varying between 0 and n2.
Figure 3: A comparison between the behaviors of exponential correlation function and squared exponential
correlation function. The term “range” refers to the correlation range parameter φ.
2.3.2 Bayesian inference
We assign the following prior distribution to the model parameters:
θ0 ∼ N(µ0, σ20), φ ∼ G(a, 1),
σ2 ∼ IG(cσ2 , dσ2), τ2 ∼ IG(cτ2 , dτ2), σ20 ∼ IG(cσ20 , dσ20 ),
where G(a, b) and IG(a, b) denote the Gamma distribution and inverse Gamma distribution, respectively, with shape
parameter a and rate parameter b. We set the rate parameter in G(a, 1) to 1 considering that the rate parameter
only affects the scale of the prior: if x ∼ G(a, 1), then βx ∼ G(a, 1/β). Note that in the early-phase basket trials,
there is usually a limited sample size per indication, and thus for all Bayesian approaches, the prior specification
will have certain impact on the posterior distribution. For CBHM, for example, smaller a in the G(a, 1) prior for
φ leads to stronger borrowing between indications. In practice, a can be chosen by simulation based on q0, q1,
distance measure, correlation function, etc. A formal instruction for the prior specification of CBHM is provided
in Appendix D.
2.3.3 Trial process
For the implementation of CBHM, we propose a two-stage design, which can be viewed as a special case of the
BLAST design (Chu and Yuan, 2018):
Step 1: in stage one, enroll ni,1 patients for the ith indication group and collect data D1 = {ni,1, Y 1ij , i =
1, . . . , I, j = 1, . . . , ni,1}, where ni,1 denotes the stage-one sample size of the ith indication group.
Step 2: at the end of stage one, apply model (1) to D1 and conduct interim analysis on each indication
i: if Pr(pi > (q0 + q1)/2|D1) < Qf , then stop enrollment early and conclude that the ith indication is not
sensitive to the treatment; otherwise, continue to stage two until a total of ni patients are enrolled.
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Step 3: at the end of the trial, assess the indication groups that continued to stage two: if Pr(pi > q0|D) > Q,
where D = {ni, Yij , i : ni,2 > 0, j = 1, . . . , ni} denotes the final data, then the ith indication is concluded to
be sensitive.
Here we use (q0 + q1)/2 as the threshold for response rate in the interim analysis considering that it has been
used in other designs as well (Chu and Yuan, 2018). Simulation results also show that the choice for the threshold
has little impact on the performance of CBHM. The probability cut-off for final decision, Q, can be calibrated to
control the type I error rate (Thall et al., 1995; Chu and Yuan, 2018).
3 Simulation Studies
3.1 Simulation settings
We conducted simulation studies to investigate the relative performance between the various approaches in Section
2. We set the null response rate to q0 = 0.2, target response rate to q1 = 0.4, and assumed that there were
I = 6 indications that belonged to either a sensitive subgroup with response rate equal to q1, or an insensitive
subgroup with response rate equal to q0. We considered various scenarios where there were 0, 1, . . . , I − 1 sensitive
indications. For a fair comparison, we applied our two-stage trial design in Section 2.3.3 to all approaches except
for Liu’s approach, which should be implemented using its own design that is slightly different and hard to fit in
our design (see Figure 1). For each indication, we set the maximum sample size to ni = 24, and conducted interim
analysis when the number of enrolled patients reached n1i = 14. This setting for ni and n1i followed the minimax
Simon’s two-stage design with power 80.0%, type I error rate 10.0%, null response rate 0.2 and target response rate
0.4 (Simon, 1989). Yij ’s were then simulated independently from Ber(pi). We set the probability cut-off for interim
analysis to Qf = 0.05, and calibrated Q, the probability cut-off for final decision, to control the type I error rate
at α = 10.0% under the null scenario.
We conducted CBHM using B distance with exponential correlation. Prior specification for the various Bayesian
models, as well as the specification of thresholds and tuning parameters for EXNEX and Liu’s approach, are
provided in Appendices A, B, C and D. We ran 5000 simulations under each scenario, and in each simulation,
we approximated the Bayesian posterior distribution using 10000 MCMC iterations after a burn-in stage of 5000
iterations, which, based on our simulation results, guaranteed the convergence of MCMC for all implemented
Bayesian models. The simulations were conducted in R with the Bayesian models being implemented using the
R package “rjags” (Plummer, 2013). The average computation time per simulation is approximately 0.6 seconds
for independent analysis, 0.8 seconds for BHM, 0.2 seconds for Liu’s heterogeneous path, 0.9 seconds for Liu’s
homogeneous path, 1.9 seconds for EXNEX, and 4.9 seconds for CBHM.
3.2 Simulation results
Tables 1-2 summarize the operating characteristics of the various approaches in different simulated scenarios. The
“true RRs” row lists the true response rate of each indication, with bold font indicating sensitivity to the treat-
ment. The “% reject” and “% stop” row report the rejection percentage for H0 and the early stopping percentage,
respectively. The “Sample Size” column reports the average sample size considering potential early stopping. We
also report the percentage of the simulations that gave correct conclusion for all indications (“% perfect”), the
average number of sensitive and insensitive indications each simulation correctly identified (“# TP” and “# TN”,
respectively). We focus our discussion on the power, type I error control and average sample size.
In the null scenario in Table 1, the type I error rate is controlled at approximately 10% for each approach, and
compared to independent analysis, all information borrowing approaches tend to stop the trial early and thus have
smaller average sample sizes. In scenario 2 where only one indication is sensitive, EXNEX, Liu’s approach and
our proposed CBHM approach have slightly lower power (78.9%, 80.7% and 79.1%, respectively) than independent
analysis (82.4%), and slightly inflated average type I error rates (14.2%, 13.4% and 14.5%, respectively). BHM, on
the other hand, has a considerably lower power (71.3%) and higher average type I error rate (18.5%). Liu’s approach
has the smallest average sample size, because its heterogeneous path uses Simon’s two-stage design that has a more
strict early stopping rule than the design for other approaches. CBHM has a similar average sample size as Liu’s
approach which is lower than that of the other approaches. In scenario 3 where there are 2 sensitive indications,
all information borrowing approaches have higher power than independent analysis, among which CBHM has the
highest average power (BHM: 83.5%, EXNEX: 84.2%, Liu’s: 84.2% and CBHM: 85.4%). EXNEX, Liu’s approach
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Table 1: Simulation results assuming 0-2 sensitive indications out of 6. For CBHM, results were obtained
using B distance with exponential correlation.
Scenario Method Results for Cancer Type: SampleSize % Perfect # TP # TN1 2 3 4 5 6
1 True RRs 0.2 0.2 0.2 0.2 0.2 0.2 0 6
(Null) Independent % reject 10.7 9.6 10.0 9.5 10.7 9.9 132.0 53.0 0.00 5.40% stop 20.2 19.8 20.1 20.2 19.6 19.8
BHM % reject 10.2 9.8 9.9 10.0 10.2 9.9 115.6 72.2 0.00 5.40% stop 47.3 47.2 47.6 47.3 47.5 47.3
EXNEX % reject 10.6 9.4 10.1 9.5 10.6 9.8 125.0 64.5 0.00 5.40% stop 32.0 31.4 31.6 31.8 31.9 31.7
Liu’s % reject 10.8 9.6 10.0 9.4 10.4 10.1 119.6 59.7 0.00 5.40% stop 40.6 40.3 40.7 41.0 40.8 40.2
CBHM % reject 10.0 10.0 9.8 10.4 9.7 9.7 119.9 63.4 0.00 5.40% stop 40.5 41.0 40.2 39.3 40.2 39.9
2 True RRs 0.4 0.2 0.2 0.2 0.2 0.2 1 5
Independent % reject 82.4 10.5 9.9 10.0 10.1 9.8 134.2 47.8 0.82 4.50% stop 0.7 18.8 20.3 19.7 19.6 19.0
BHM % reject 71.3 18.2 18.5 18.9 18.5 18.5 129.4 29.0 0.71 4.07% stop 7.4 27.8 28.0 27.3 28.0 27.5
EXNEX % reject 78.9 14.2 14.3 14.5 14.0 14.2 132.5 39.7 0.79 4.29% stop 2.4 22.1 22.5 22.9 22.7 22.1
Liu’s % reject 80.7 13.9 13.1 13.5 13.2 13.5 125.2 41.4 0.81 4.32% stop 3.4 36.3 37.4 36.6 37.5 36.9
CBHM % reject 79.1 14.2 14.3 14.1 15.0 14.9 126.5 36.2 0.79 4.28% stop 3.7 34.4 33.7 34.7 34.6 34.1
3 True RRs 0.4 0.4 0.2 0.2 0.2 0.2 2 4
Independent % reject 81.3 81.2 10.2 9.6 9.8 9.8 135.8 43.8 1.62 3.62% stop 0.9 0.9 19.4 20.0 20.0 21.1
BHM % reject 83.4 83.5 27.1 25.8 26.7 25.4 137.0 26.8 1.67 2.95% stop 3.3 3.2 15.3 16.1 16.2 16.3
EXNEX % reject 84.3 84.0 18.5 18.1 18.8 17.7 136.6 33.1 1.68 3.27% stop 1.5 1.5 17.2 18.0 17.2 18.7
Liu’s % reject 84.0 84.4 16.3 15.7 16.4 15.2 129.1 37.1 1.68 3.37% stop 3.0 2.6 35.0 36.7 35.0 36.3
CBHM % reject 85.1 85.7 16.9 16.7 16.5 15.9 131.6 33.4 1.71 3.33% stop 3.2 2.4 29.0 30.2 29.7 29.8
and CBHM have less inflated average type I error rates (18.5%, 15.9% and 16.5%, respectively) than BHM (26.3%).
BHM and EXNEX have the highest average sample sizes, while Liu’s approach and CBHM have the lowest.
In Table 2 where 3-5 indications are sensitive, Liu’s approach has the smallest average sample size because
of its more strict early stopping rule, but overall all approaches have similar average sample sizes. Compared to
scenarios 2-3, all information borrowing approaches now show more advantage in power compared to independent
analysis. When 3 indications are sensitive, BHM has a substantially higher average power than independent analysis
(90.0% versus 81.3%), but also a highly inflated average type I error rate (35.7%). EXNEX and Liu’s approach
have lower average power (88.0% and 86.3%, respectively) and lower average type I error rates (23.0% and 20.1%,
respectively). CBHM has an similar average power as EXNEX (88.7%), and the best controlled type I error
rate among the information borrowing approaches (average: 19.4%). Results are similar when 4-5 indications are
sensitive, and we observe a more clear advantage of CBHM over other information borrowing approaches especially
in terms of type I error control: although BHM and EXNEX provide higher power than CBHM, the highly inflated
type I error rates make their conclusions possibly unreliable. CBHM, on the contrary, provides a higher power than
Liu’s approach and substantially better control of type I error than all other information borrowing approaches.
We also summarized the absolute bias and root mean square error (RMSE) of the estimated response rates
on Web Appendix. Briefly, all approaches have similar absolute bias and RMSE. Liu’s approach has the largest
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Table 2: Simulation results assuming 3-5 sensitive indications out of 6. For CBHM, results were obtained
using B distance with exponential correlation.
Scenario Method Results for Cancer Type: SampleSize % Perfect # TP # TN1 2 3 4 5 6
4 True RRs 0.4 0.4 0.4 0.2 0.2 0.2 3 3
Independent % reject 81.6 81.0 81.3 10.0 10.0 9.8 137.8 39.8 2.44 2.70% stop 0.8 0.8 0.8 19.5 19.9 19.8
BHM % reject 89.9 89.7 90.5 36.3 35.7 35.0 141.3 25.6 2.70 1.93% stop 1.3 1.0 1.2 8.2 7.6 7.7
EXNEX % reject 88.0 87.7 88.3 23.8 22.8 22.3 139.6 33.1 2.64 2.31% stop 0.7 0.9 0.9 13.7 13.7 13.6
Liu’s % reject 86.7 85.8 86.3 20.4 20.2 19.6 132.8 34.9 2.59 2.40% stop 2.8 3.1 2.6 35.0 34.7 34.2
CBHM % reject 88.9 88.5 88.7 20.2 19.2 18.8 136.3 37.4 2.66 2.42% stop 2.2 2.3 2.2 24.3 23.1 23.3
5 True RRs 0.4 0.4 0.4 0.4 0.2 0.2 4 2
Independent % reject 81.1 81.3 81.8 82.5 9.8 10.1 139.6 35.9 3.27 1.80% stop 1.0 0.9 1.0 0.9 20.0 20.0
BHM % reject 93.4 93.7 94.0 94.1 46.0 46.7 143.1 25.7 3.75 1.07% stop 0.4 0.4 0.5 0.4 3.7 4.0
EXNEX % reject 91.1 91.3 91.6 92.0 28.0 28.9 141.7 35.3 3.66 1.43% stop 0.6 0.6 0.7 0.7 10.4 10.2
Liu’s % reject 87.8 87.4 87.6 89.0 24.5 24.6 135.7 32.1 3.52 1.51% stop 3.1 2.9 3.1 2.4 35.8 35.2
CBHM % reject 90.1 90.3 90.7 91.1 20.9 21.8 139.8 41.6 3.59 1.58% stop 1.6 1.5 1.7 1.6 17.8 17.6
6 True RRs 0.4 0.4 0.4 0.4 0.4 0.2 5 1
Independent % reject 81.7 83.0 82.0 81.6 80.7 10.3 141.6 32.3 4.09 0.90% stop 0.8 0.8 0.9 0.8 0.9 19.7
BHM % reject 96.7 96.9 97.0 96.7 96.6 63.1 143.8 25.7 4.84 0.37% stop 0.1 0.2 0.1 0.1 0.1 1.0
EXNEX % reject 93.6 93.6 93.9 93.6 93.3 33.6 143.2 45.5 4.68 0.66% stop 0.3 0.4 0.4 0.3 0.3 6.8
Liu’s % reject 89.2 89.9 90.1 89.6 89.3 32.0 139.0 35.8 4.48 0.68% stop 2.7 3.0 2.9 3.0 2.9 36.0
CBHM % reject 91.1 91.6 91.2 90.8 90.6 25.6 142.4 43.6 4.55 0.74% stop 0.8 1.1 1.1 0.9 1.2 10.7
average absolute bias and RMSE in all studied scenarios except for the null scenario, where independent analysis
has slightly larger average absolute bias and RMSE. Among information borrowing approaches, BHM, EXNEX
and Liu’s approach tend to have large absolute bias and RMSE for the outliers (i.e. the indications whose response
rates differ from those of the majorities). CBHM, however, has more robust estimation with smaller absolute bias
and RMSE for the outliers, as well as smaller abolute bias and RMSE than Liu’s approach in all studied scenarios.
3.3 Sensitivity Analysis
The simulation results of CBHM in Tables 1-2 were obtained using B distance. We also conducted simulations
using KL and H distance to evaluate the sensitivity of CBHM with respect to the choice for distance measure. The
operating characteristics of CBHM using different distance measures are summarized in Table 3, from which we
can observe that the B distance and H distance lead to similar performance of CBHM, as well as similar relative
performance between CBHM and other considered approaches. The KL distance, on the other hand, tends to have
lower power, more strict type I error control, and requires more complex procedure for prior specification. Note
that different distance measures need to be implemented along with different correlation functions and priors. A
detailed instruction and additional simulation results are provided on Web Appendix. In practice, we recommend
B distance with exponential correlation function given the promising performance and simple procedure required
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Table 3: Simulation results of CBHM using different distance measures. “CBHM-B”, “CBHM-KL” and
“CBHM-H” denote the CBHM using B, KL and H distance, respectively.
Scenario Method Results for Cancer Type: SampleSize % Perfect # TP # TN1 2 3 4 5 6
1 True RRs 0.2 0.2 0.2 0.2 0.2 0.2 0 6
CBHM-B % reject 10.0 10.0 9.8 10.4 9.7 9.7 119.9 63.4 0.00 5.40% stop 40.5 41.0 40.2 39.3 40.2 39.9
CBHM-KL % reject 10.5 9.4 10.1 9.3 10.6 10.0 123.6 54.6 0.00 5.31% stop 37.4 37.3 37.9 37.5 37.0 36.9
CBHM-H % reject 9.5 10.3 10.1 10.9 9.3 9.6 121.9 62.6 0.00 5.40% stop 37.0 37.3 36.3 34.4 38.8 37.2
2 True RRs 0.4 0.2 0.2 0.2 0.2 0.2 1 5
CBHM-B % reject 79.1 14.2 14.3 14.1 15.0 14.9 126.5 36.2 0.79 4.28% stop 3.7 34.4 33.7 34.7 34.6 34.1
CBHM-KL % reject 82.5 12.5 12.4 12.3 12.7 12.8 127.3 43.4 0.83 4.37% stop 3.2 32.8 33.1 32.6 32.8 31.9
CBHM-H % reject 79.8 13.8 14.1 13.8 14.5 14.6 129.8 39.2 0.80 4.29% stop 2.9 27.8 27.7 28.2 28.0 27.3
3 True RRs 0.4 0.4 0.2 0.2 0.2 0.2 2 4
CBHM-B % reject 85.1 85.7 16.9 16.7 16.5 15.9 131.6 33.4 1.71 3.33% stop 3.2 2.4 29.0 30.2 29.7 29.8
CBHM-KL % reject 83.3 83.2 14.3 13.6 14.4 13.7 132.2 37.8 1.67 3.44% stop 2.6 2.5 27.7 28.3 28.2 29.2
CBHM-H % reject 85.5 85.4 17.0 16.1 17.4 16.9 135.2 35.8 1.71 3.33% stop 2.0 2.2 20.5 21.6 20.9 20.8
4 True RRs 0.4 0.4 0.4 0.2 0.2 0.2 3 3
CBHM-B % reject 88.6 88.8 88.7 19.2 20.2 18.8 136.3 37.4 2.66 2.42% stop 2.2 2.3 2.2 24.3 23.1 23.3
CBHM-KL % reject 85.3 84.7 85.4 16.0 16.2 15.2 136.6 37.6 2.55 2.53% stop 2.0 2.0 1.9 22.7 22.7 22.8
CBHM-H % reject 88.4 87.9 88.2 19.8 20.3 19.0 139.3 36.3 2.65 2.41% stop 1.2 1.3 1.3 14.8 14.2 13.8
5 True RRs 0.4 0.4 0.4 0.4 0.2 0.2 4 2
CBHM-B % reject 90.1 90.3 91.1 90.7 20.9 21.8 139.8 41.6 3.59 1.58% stop 1.6 1.5 1.7 1.6 17.8 17.6
CBHM-KL % reject 86.4 86.2 86.6 87.7 17.0 17.1 139.8 38.3 3.47 1.66% stop 1.6 1.5 1.5 1.1 17.6 18.3
CBHM-H % reject 89.3 89.9 90.6 89.9 24.6 24.1 141.8 38.0 3.60 1.51% stop 0.7 0.6 0.6 0.7 10.0 9.7
6 True RRs 0.4 0.4 0.4 0.4 0.4 0.2 5 1
CBHM-B % reject 91.1 91.6 91.2 90.8 90.6 25.6 142.4 43.6 4.55 0.74% stop 0.8 1.1 1.1 0.9 1.2 10.7
CBHM-KL % reject 88.6 89.0 88.8 88.1 87.9 18.7 142.6 48.8 4.52 0.81% stop 0.1 0.6 0.9 0.8 0.7 10.4
CBHM-H % reject 92.0 92.2 92.4 91.6 91.7 30.5 143.2 41.2 4.60 0.69% stop 0.3 0.3 0.4 0.4 0.4 6.0
for prior specification.
So far, we have discussed simulation studies assuming a total of I = 6 indications. We also investigated the
performance of the various approaches when I = 3 and 12. The rejection and early stopping percentages are
reported in Figures 4-5. When I = 3, EXNEX, Liu’s approach and CBHM have similar performance, with lower
power and more strict type I error control than BHM. When I = 12, BHM and EXNEX show potential advantage
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Figure 4: The rejection percentage (i.e. the power for the sensitive indications and type I error rate
for the insensitive indications, sub-figure 1) and early stopping percentage at interim analysis (sub-figure
2) assuming there are I = 3 indications. CBHM was implemented using B distance with exponential
correlation. The indications whose indexes on the x-axis are circled and marked in bold are sensitive to
the targeted treatment, while the others are insensitive.
Figure 5: Rejection percentage (i.e. power for the sensitive indications and type I error rate for the
insensitive indications, sub-figure 1) and early stopping percentage at interim analysis (sub-figure 2)
assuming there are I = 12 indications. The indications whose indexes on the x-axis are circled and
marked in bold are sensitive to the targeted treatment, while the others are insensitive.
in power but only when a large proportion of the indications (e.g. > 9 out of 12) are truly sensitive. They also
have poor type I error control and low early stopping percentage. The advantage of CBHM is highlighted, with
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a promising power similar to Liu’s approach, substantially better control of type I error rate compared to BHM,
EXNEX and Liu’s approach, and a high early stopping percentage. Overall, as the total number of indications
increases, the difference between the various approaches and the advantage of CBHM become more clear.
Table 4: The various priors considered for σ2, τ2 and φ in sensitivity analysis.
Prior Setting σ2, τ2 φ
1 IG(0.1, 0.1) G(1, 1)
2 IG(0.01, 0.01) G(1, 1)
3 IG(0.001, 0.001) G(1, 1)
4 IG(0.01, 0.01) G(0.7, 1)
We also conducted sensitivity analysis for the prior specification of CBHM. The prior for the between- and
within-indication variance parameters (σ2 and τ2, respectively) can have impact on the posterior distribution due
to limited data. We therefore considered two other priors: IG(0.1, 0.1) and IG(0.001, 0.001), in addition to the
IG(0.01, 0.01) prior in Section 3.2, for σ2 and τ2. Following our instruction for prior specification in Appendix D,
a G(a, 1) prior with a ∈ [0.70, 1.21] is reasonable for the correlation range parameter, φ. We therefore considered
another G(0.7, 1) prior as a comparison with the G(1, 1) prior in Section 3.2. Table 4 summarizes the four prior
settings we considered for {σ2, τ2, φ}, while the prior for the rest of the model parameters remains the same as
that in Section 3.2. Table 5 summarizes the simulation results. Overall, different priors for σ2 and τ2 lead to
similar performance of CBHM, but a IG(c, c) prior with smaller c tends to induce stronger borrowing that leads
to higher power and type I error rate. We recommend the IG(0.01, 0.01) prior for application given its promising
performance, but different priors can be considered depending on the primary focus, e.g. higher power or more
strict type I error control. Regarding the two priors for φ that were both selected based on our instruction for prior
specification, G(0.7, 1) leads to slightly higher power and type I error rate than G(1, 1), but overall the results are
similar. This suggests that the performance of CBHM is consistent under different choices for a in the G(a, 1) prior
for φ, if a is selected according to our instruction.
We also conducted a simulation study assuming more moderate treatment effect with q1 = 0.3 instead of 0.4.
Simulation results are summarized on Web Appendix, from which we observe a similar pattern of the relative
performance between approaches as when q1 = 0.4. When 0-2 of the 6 indications are sensitive, all approaches have
similar and more promising performance than BHM in terms of power and type I error control. When 3-5 of the 6
indications are sensitive, CBHM has a power lower than BHM and EXNEX but higher than Liu’s approach, and
a similar type I error rate as Liu’s approach that is much lower than that of BHM and EXNEX.
As a summary, Table 6 lists a comparison between the various approaches in terms of power, type I error
control and design complexity. Regarding design complexity, CBHM avoids the need to conduct subgroup clustering
required for EXNEX and the heterogeneity test required for Liu’s approach, therefore has fewer tuning parameters
and a simpler design. BHM is the least recommended due to the potentially huge inflation in type I error rate.
Overall, the independent analysis has the advantage of strong type I error control and easy implementation, and
is recommended when there is a priori information that only a small proportion (e.g. 1 out of 6) of the indications
might be sensitive to the treatment. Our CBHM approach has the advantage of high detection power and potentially
much better type I error control than BHM, EXNEX and Liu’s approach. It is especially recommended when there
is a relatively large number of indications in the basket (e.g. I > 3), and when prior knowledge suggests that a
relatively large proportion of the indications are sensitive to the treatment.
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Table 5: Operating characteristics of CBHM using different priors for φ, σ2 and τ2.
Scenario Design Results for Cancer Type: SampleSize % Perfect # TP # TN1 2 3 4 5 6
1 True RRs 0.2 0.2 0.2 0.2 0.2 0.2 0 6
Prior 1 % reject 10.3 9.9 10.6 9.6 9.9 9.9 121.1 57.7 0.00 5.38% stop 38.2 39.0 38.3 37.0 38.5 38.2
Prior 2 % reject 10.0 10.0 9.8 10.4 9.7 9.7 119.9 63.4 0.00 5.40% stop 40.5 41.0 40.2 39.3 40.2 39.9
Prior 3 % reject 10.1 10.0 10.2 10.3 9.8 10.1 118.1 57.9 0.00 5.42% stop 43.5 44.1 42.9 42.3 43.4 42.5
Prior 4 % reject 10.3 10.8 9.9 10.6 9.6 9.8 119.9 62.7 0.00 5.37% stop 40.7 40.9 40.1 39.2 40.7 39.8
2 True RRs 0.4 0.2 0.2 0.2 0.2 0.2 1 5
Prior 1 % reject 81.6 13.4 13.6 12.9 13.7 13.9 126.7 41.9 0.82 4.33% stop 3.2 34.6 33.1 34.0 34.2 33.7
Prior 2 % reject 79.1 14.2 14.3 14.1 15.0 14.9 126.5 36.2 0.79 4.28% stop 3.7 34.4 33.7 34.7 34.6 34.1
Prior 3 % reject 77.3 15.8 16.2 15.8 16.3 16.5 126.0 44.7 0.82 4.41% stop 5.1 35.4 34.4 35.6 34.7 34.9
Prior 4 % reject 79.1 15.0 14.4 14.8 15.6 15.7 126.6 34.3 0.80 4.22% stop 3.9 34.4 33.6 34.7 33.8 33.7
3 True RRs 0.4 0.4 0.2 0.2 0.2 0.2 2 4
Prior 1 % reject 84.5 85.1 16.2 14.9 15.8 15.0 131.5 34.7 1.70 3.37% stop 2.6 3.0 29.7 31.0 28.8 29.9
Prior 2 % reject 85.1 85.7 16.9 16.7 16.5 15.9 131.6 33.4 1.71 3.33% stop 3.2 2.4 29.0 30.2 29.7 29.8
Prior 3 % reject 86.3 86.2 19.7 18.5 19.9 19.3 131.5 38.1 1.67 3.44% stop 3.5 3.5 29.3 30.3 29.1 29.7
Prior 4 % reject 85.8 86.2 18.3 17.0 17.9 18.0 131.7 33.3 1.73 3.26% stop 2.8 3.0 28.9 30.0 28.9 29.4
4 True RRs 0.4 0.4 0.4 0.2 0.2 0.2 3 3
Prior 1 % reject 87.6 87.9 87.4 17.4 18.0 17.1 135.9 37.5 2.63 2.48% stop 2.1 2.1 2.2 25.9 24.6 24.5
Prior 2 % reject 88.6 88.8 88.7 19.2 20.2 18.8 136.3 37.4 2.66 2.42% stop 2.2 2.3 2.2 24.3 23.1 23.3
Prior 3 % reject 89.6 89.5 89.6 22.0 22.5 21.6 136.3 37.5 2.58 2.52% stop 2.1 2.5 2.4 24.1 22.9 22.8
Prior 4 % reject 89.0 89.0 88.7 20.4 20.8 20.0 136.5 36.7 2.68 2.38% stop 2.1 2.3 2.2 23.4 22.2 23.2
5 True RRs 0.4 0.4 0.4 0.4 0.2 0.2 4 2
Prior 1 % reject 88.7 89.0 89.9 88.9 19.2 18.1 139.5 41.2 3.56 1.63% stop 1.6 1.4 1.5 1.5 20.2 20.3
Prior 2 % reject 90.1 90.3 91.1 90.7 20.9 21.8 139.8 41.6 3.59 1.58% stop 1.6 1.5 1.7 1.6 17.8 17.6
Prior 3 % reject 90.0 90.5 91.4 90.9 24.6 24.3 140.0 39.0 3.49 1.65% stop 1.7 1.5 1.6 1.6 16.8 16.8
Prior 4 % reject 89.6 90.3 91.2 90.2 23.2 22.8 140.1 39.2 3.62 1.53% stop 1.5 1.4 1.4 1.3 16.8 16.8
6 True RRs 0.4 0.4 0.4 0.4 0.4 0.2 5 1
Prior 1 % reject 90.5 91.1 90.7 90.3 89.9 25.0 142.5 43.0 4.56 0.73% stop 1.0 0.9 1.0 0.9 1.2 10.3
Prior 2 % reject 91.1 91.6 91.2 90.8 90.6 25.6 142.4 43.6 4.55 0.74% stop 0.8 1.1 1.1 0.9 1.2 10.7
Prior 3 % reject 92.0 92.1 92.0 91.7 91.2 29.1 142.4 51.1 4.55 0.82% stop 1.0 1.0 1.1 0.9 1.2 10.2
Prior 4 % reject 91.6 91.8 92.0 91.2 91.1 27.7 142.5 43.3 4.58 0.72% stop 1.0 0.9 1.0 0.9 1.1 10.113
Table 6: Comparison between the various approaches considered. The number of “?” indicates the pref-
erence level (more “?” indicates higher level of preference), and “X” indicates that a approach is recom-
mended.
Method Power Type I ErrorControl
Design
Complexity Overall
Independent ? ? ? ? ? ? ? ? ? X
BHM ? ? ? ? ? ? ?
EXNEX ? ? ? ?? ?
Liu’s ?? ? ? ? ?
CBHM ?? ? ? ?? ?? X
4 Discussion
We discuss several representative Bayesian methods for basket trials in early-phase oncology studies that borrow
information across indications, including BHM, EXNEX and Liu’s approach, and propose a novel method called
CBHM, which conducts flexible information borrowing according to pairwise sample similarity of the indications.
Simulation results show the advantage as well as the drawback of information borrowing: it potentially provides
substantially higher power, but the type I error rate will be inflated as well. Among the considered information
borrowing approaches, BHM only demonstrates clear advantage in terms of power when a large proportion (e.g. 5
out of 6) of the indications are sensitive, and has the highest inflation in type I error rate that can be unacceptable
even for early-phase trials. Our CBHM approach has the most robust performance, with a power similar to that
of EXNEX or Liu’s approach depending on the data scenario, and type I error control that can be substantially
better than that of BHM, EXNEX and Liu’s approach.
In the early-phase basket trials, type I error control is not our primary focus, and thus various approaches
have been proposed to improve the power by sacrificing strong control of type I error rate. However, the inflated
type I error rate should still be concerned while focusing on improving the detection power. According to our
simulation results, BHM and EXNEX can have type I error rates inflated from 10% to 33.6% − 63.1% when 5
of the 6 indications are sensitive. This is a huge inflation that can raise serious concerns about the validity of
the conclusions, suggesting that we should be cautious when determining if it is worth conducting an information
borrowing approach. In this sense, the advantage of CBHM in terms of type I error control can be quite meaningful
in clinical application.
In general, certain things should be kept in mind when implementing a Bayesian information borrowing ap-
proach. First, the prior specification needs careful consideration due to limited sample size. For CBHM, for
example, the prior for the correlation range parameter, φ, should be specified based on the null and target response
rates, distance measure and correlation function, to induce a reasonable amount of borrowing. Second, in the cur-
rent setting, we assume that all indications have the same null and target response rates for simplicity. In reality,
the trial setting can be more complex. For example, the null response rates, q0,i’s, and the target response rates,
q1,i’s, may vary by indication. Our CBHM approach, however, can be easily extended to apply to this general case
after slight modification. Given these practical concerns, we provide CBHM with a detailed instruction for the
prior specification and trial process in a general setting. This type of general guidance is not provided by most
existing approaches, including EXNEX and Liu’s approach, which ensures the applicability of CBHM in a wider
range of trials with more complex settings. In summary, for a specific trial, simulation studies should be conducted
to determine the prior for the model parameters and the optimal approach for analysis (e.g. independent analysis
or information borrowing approaches such as BHM or CBHM), in order to have our desired power and type I error
rate.
We conducted CBHM using the R package “rjags”, which on average takes approximately 17 minutes to complete
the simulations under one data scenario if conducting parallel computing across simulations using 24 cores. Although
rjags is sufficient for our current simulation, we can consider other software, such as STAN (Carpenter et al, 2017),
for future application, which can potentially improve the computational efficiency of the modeling process. The
current CBHM approach restrains borrowing between heterogeneous indications by assigning a correlation close
to zero between indications that have large difference in sample response rates. However, it still leads to inflated
type I error rate, and, ideally, we would like to avoid information borrowing between a sensitive and an insensitive
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indication. This inspires us to modify CBHM to achieve more strict type I error control, for example, to truncate
the correlation between two indications when the difference in sample response rates exceeds a threshold. We leave
this extension of CBHM for future work.
5 Software
The R code for simulation studies and the implementation of CBHM in a general trial setting, as well as the simu-
lated data sets that were used to produce the presented simulation results, are available at https://github.com/Jin93/CBHM.
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Appendix A. Prior specification for BHM
For the conventional BHM, it is assumed that Yij
iid∼ Ber(pi), and the log odds parameters, {θi = log(pi/(1− pi)),
i = 1, 2, . . . , I}, follow a common prior N(θ0, σ2), where θ0 ∼ N(g0, σ20) with g0 = log(q0/(1 − q0)), σ20 = 1000,
and σ2 ∼ IG(aσ2 , bσ2) with aσ2 = bσ2 = 0.001. Here IG(a, b) denotes the inverse Gamma distribution with shape
parameter a and rate parameter b.
Appendix B. Prior specification for EXNEX
Recall that EXNEX has the following model setup:
Yij ∼Ber(pi),
θi = log
pi
1− pi ,
θi = δiMi1 + (1− δi)Mi2,
δi ∼ Ber(pii), Mi1 ∼ N(µ0, σ20), Mi2 ∼ N(µi, σ2i ).
The prior specification for EXNEX used in this paper follows the one that was used in the original paper (Neuen-
schwander et al., 2016):
µ0 ∼N(0, τ20 ),
σ20 ∼ TrN(0,100, (0.001,+∞)),
(pii, 1− pii) ∼ Dir(λ1, λ2),
where TrN(a, b, (L,U)) denotes the truncated normal distribution on the interval (L,U), and
Dir(λ1, λ2, . . . , λK) denotes the Dirichlet distribution with probability parameters (λ1, λ2, . . . , λK). Note that pii’s
and 1− pii’s, i.e. the weights of EX and NEX components, respectively, can be assumed as fixed and pre-specified
by users, or alternatively, as done in our simulation studies, can be inferred along with the other parameters
via a Dirichlet prior. The specification for hyperparameters follows Neuenschwander et al. (2016): τ20 = 5,
µi = log(q0/(1 − q0)), and σ2i = 1/0.15, i = 1, 2, . . . , I. The current EXNEX model assumes only one EX
component, which, in some cases, may be too restrictive. The extension to more than one EX component is
technically straightforward, but will require careful consideration for the choice of mixture weights and priors
(details can be found in Neuenschwander et al., 2016). Under the simulation setting presented in this paper, a
single EX component is adequate to illustrate the performance of EXNEX.
Appendix C. Prior specification for Liu’s two-path design
For Liu’s two-path design, we set the threshold for the test statistics of the homogeneous test as γ = 0.2, which
was used in the original paper (Liu et al., 2017). The heterogeneous path follows Simon’s two-stage design, and
there is no model parameter to estimate or calibrate. For the homogeneous path, we set the probability threshold
for futility stopping at interm analysis to C = 0.5, which was also used in Liu et al. (2017). The model and prior
specification for stage one is described in Section 2.2.2 of the main manuscript. For stage two, a BHMM with two
mixture components is applied to the final data:
Yij ∼Ber(pi),
θi = log
pi
1− pi
θi = δiMi1 + (1− δi)Mi2,
δi ∼ Ber(pii), Mi1 ∼ N(µ1, σ21), Mi2 ∼ N(µ2, σ22),
and the prior specification follows Liu et al. (2017):
µ1 ∼ N(g1, τ21 ), µ2 ∼ N(g2, τ22 ),
σ21 ∼ IG(a1, b1), σ22 ∼ IG(a2, b2).
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In the simulation studies in Liu et al. (2017), g1 and g2 were specified to be −2.2 and −1.1, respectively, which, in
their simulation setting, are g1 = log(q0/(1−q0)), and g2 = log(q1/(1−q1)), respectively. In our simulation setting,
we used the same strategy for prior specification and set g1 = log(q0/(1−q0)) = −1.38, and g2 = log(q1/(1−q1)) =
−0.41. For the rest of the hyperparameters, we set τ21 = 1/0.42, τ22 = 1/0.57, a1 = a2 = b1 = b2 = 0.1, and
pii = 0.5, i = 1, 2, . . . , I, which were also used in Liu et al. (2017).
Appendix D. Detailed discussion on CBHM
D.1. Prior specification for CBHM in the presented simulation studies
Recall that the model setup for CBHM is:
Yij ∼Ber(pi),
θi = log
pi
1− pi ,
θi = θ0 + ηi + i,
η ∼MVN (0, σ2R(φ)), i i.i.d.∼ N(0, τ2).
Now we introduce how we specified the prior for CBHM used in the simulation studies discussed in Section
3.2 of the main manuscript. Briefly, we first specify the prior for the correlation range parameter φ based on the
distance measure, a distance threshold dt, a correlation threshold %, and the choice for correlation function. We
then specify the prior for the rest of the parameters.
For the prior specification of φ, the first step is to select a distance measure. Theoretically, any well-defined
distance measure for probability distributions can be used.
We first use B distance as an example, which, in our beta-binomial case, can be written as:
dBi,j = − log
B
(
ri+rj+2
2 ,
ni+nj−ri−rj+2
2
)
√
B(1 + ri, 1 + ni − ri)B(1 + rj , 1 + nj − rj)
,
where B(a, b) denotes the Beta function, and the other notations are introduced in Section 2.3.1 of the main
manuscript.
Figure S1 shows the sample distribution of B distance between two indications in the following scenarios: (1)
p1 = p2 = q0, (2) p1 = p2 = q1, (3) p1 = q0, p2 = q1, where q0 and q1 denote the null response rate and target
response rate, respectively. In the two homogeneous cases (1) and (3) (sub-figures 1 and 3 of Figure S1), the 95%
Figure 6: Example plots showing the sample distribution of B distance between two indications when (1)
p1 = p2 = q0, (2) p1 = p2 = q1, and (3) p1 = q0, p2 = q1, respectively. Results were obtained from 10000
simulations in each case. Sample sizes are fixed to n1 = n2 = 24, the null response rate is set to q0 = 0.2
and the target response rate is set to q1 = 0.4.
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quantile of the sample distance is dt = 0.995, which will be used as a threshold for distance that helps us determine
if a pair of indications is homogeneous: if the distance is smaller than dt, then we say that the two indications are
homogeneous and that we want to conduct strong information borrowing between them by assigning them with a
high prior correlation. We also set a correlation threshold, %, for information borrowing: we would like to assign
a prior correlation higher than % between homogeneous indications, and a prior correlation lower than % between
heterogeneous indications. Simulation results show that a value between 0.3 and 0.5 can be a reasonable choice for
%.
Finally, we choose the correlation function. Under exponential correlation, given the distance threshold dt =
0.995, a correlation within the interval [0.3, 0.5] corresponds to a φ within the interval [− log(0.5)/dt,− log(0.3)/dt] =
[0.70, 1.21], meaning that any value within this interval can be a choice for the prior mean of φ. In the simulation
studies presented in Section 3.2 of the main manuscript, we set this prior mean to 1. Note that for B distance,
the squared correlation function is unrealistic because of its strong smoothness. A simple example to illustrate this
point is that if we use the squared exponential correlation with φ = 1, when p1 = p2 = 0.2, approximately 33.54%
of the sample distance will fall into [0, 0.032], meaning that the prior correlations we assign to 33.54% of the pairs
of indications are greater than e−0.032
2% > 0.9994. This correlation structure is unreasonable, and can easily cause
computational issue for the MCMC algorithm.
We now discuss the prior specification for φ. We consider a Gamma prior, G(a, 1), with rate parameter equal
to 1, which converges to the normal distribution N(a,
√
a). The rate parameter is set to 1 because it only affects
the scale of the distribution: if x ∼ G(a, 1), then βx ∼ G(a, 1/β). As discussed in the previous paragraph, we
would like to set the prior mean of φ to 1, which, for the G(a, 1) prior, means that a = 1, i.e. a G(1, 1) prior for φ.
Finally, we specify the priors for the rest of the model parameters:
θ0 ∼ N(µ0, σ20), σ2 ∼ IG(cσ2 , dσ2), τ2 ∼ IG(cτ2 , dτ2), σ20 ∼ IG(cσ20 , dσ20 ),
where the hyperparameters are set to: µ0 = log(((q0 + q1)/2)/(1− (q0 + q1)/2)), cτ2 = dτ2 = cσ2 = dσ2 = 0.01, and
cσ20 = dσ20 = 0.1, to ensure that the priors are only weakly informative.
In the previous paragraphs, we discussed the prior specification of CBHM using the B distance. We now discuss
the prior specification of CBHM using the H distance. Note that given a non-informative Beta(1, 1) prior, pi and
pj have posteriors Beta(1 + ri, 1 + ni − ri) and Beta(1 + rj , 1 + nj − rj), respectively, and the H distance, dHi,j , can
be written as:
dHi,j =
√√√√
1−
B
(
ri+rj+2
2 ,
ni+nj−ri−rj+2
2
)
√
B(1 + ri, 1 + ni − ri)B(1 + rj , 1 + nj − rj)
.
Following a similar procedure as the one used for B distance, we first simulate sample distribution of H distance
in the following scenarios: (1) p1 = p2 = q0, (2) p1 = p2 = q1, (3) p1 = q0, p2 = q1 (see Figure S2). In the
two homogeneous cases (1) and (3) (sub-figures 1 and 3 of Figure S2), the 95% quantile of the sample distance is
dt = 0.793, which will be used as the distance threshold. For H distance, we also use the exponential correlation
function since the squared correlation is still not appropriate due to the reason similar to the one when using B
distance. We still set the correlation threshold to % ∈ [0.3, 0.5]. Given distance dt = 0.793, the prior mean of φ
can be selected within the interval [− log(0.5)/dt,− log(0.3)/dt] = [0.87, 1.52]. In the simulation studies discussed
in this paper, we set the prior mean of φ to 1.5, which, for the G(a, 1) prior, means that a = 1.5. The priors for
the rest of the model parameters are specified as:
θ0 ∼ N(µ0, σ20), σ2 ∼ IG(cσ2 , dσ2), τ2 ∼ IG(cτ2 , dτ2), σ20 ∼ IG(cσ20 , dσ20 ),
where the hyperparameters are set to: µ0 = log(((q0 + q1)/2)/(1− (q0 + q1)/2)), cτ2 = dτ2 = cσ2 = dσ2 = 0.01, and
cσ20 = dσ20 = 0.1.
We now discuss the prior specification of CBHM using the KL distance. The simulated sample distribution
in the various data scenarios is shown in Figure S3. In the two homogeneous cases (sub-figures 1 and 3 of Figure
S3), the 95% quantile of the sample distance is dt = 2.710, which will be used as the distance threshold. Since
KL distance changes much faster than B distance and H distance as pˆ1 − pˆ2 changes, we consider a more smooth
correlation function, the squared exponential correlation function. Given dt = 2.710, the prior mean of φ can be
selected within the interval [
√− log(0.5)/dt,√− log(0.3)/dt] = [0.094, 0.164]. Theoretically, we could still use a
G(a, 1) prior for φ with a ∈ [0.094, 0.164]. However, if using the R package “rjags” to run MCMC, some adjustments
should be made to solve the potential issue that in some rare cases, the draw of φ, σ2 and τ2 leads to singular
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Figure 7: Example plots showing the sample distribution of H distance between two indications when
p1 = p2 = q0, p1 = p2 = q1, and p1 = q0, p2 = q1, respectively. Results were obtained from 10000
simulations in each case. Sample sizes are fixed to n1 = n2 = 24, the null response rate is set to q0 = 0.2
and the target response rate is set to q1 = 0.4.
Figure 8: Example plots showing the sample distribution of KL distance between two indications when
p1 = p2 = q0, p1 = p2 = q1, and p1 = q0, p2 = q1, respectively. Results were obtained from 10000
simulations in each case. Sample sizes are fixed to n1 = n2 = 24, the null response rate is set to q0 = 0.2
and the target response rate is set to q1 = 0.4.
between-indication covariance matrix, σ2R(φ). This is because in some MCMC iterations the sampled φ or σ2
is too close to 0. We can solve this problem by writing our own MCMC algorithm instead of using rjags. For
easy implementation using rjags, we modify the prior distribution and constrain the scale of the hyperparameters
to avoid having MCMC draws that may generate singular σ2R(φ): instead of using the G(a, 1) prior, we use a
Unif(a, b) prior for φ with a > 0. In the two homogeneous cases (sub-figures 1 and 3 of Figure S3), the minimum
value of the nonzero distances is dt = 0.0727. To ensure that the corresponding correlation is less than 0.999, φ
has to be larger than 0.189. We therefore set a Unif(0.189, 0.5) prior for φ. The prior for the rest of the model
parameters is specified as follows:
θ0 ∼ N(µ0, σ20), φ ∼ Unif(a, b),
σ2 ∼ IG(cσ2 , dσ2), τ2 ∼ IG(cτ2 , dτ2), σ20 ∼ IG(cσ20 , dσ20 ),
where the hyperparameters are set to: µ0 = log(((q0 + q1)/2)/(1− (q0 + q1)/2)), a = 0.189, b = 0.5, cτ2 = cσ2 = 2,
dσ2 = 3, dτ2 = 4, and cσ20 = dσ20 = 0.1. Note that the prior for τ
2 and σ2 should also be carefully chosen to ensure
than no extremely small valued-draws are sampled in MCMC. Here we use a Unif(2, 4) prior for τ2 and a Unif(2, 3)
prior for σ2.
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Overall, the prior specification given squared correlation function is more complex and harder than that given
exponential correlation function. We have discussed the prior specification given squared correlation function so as
to show that CBHM is applicable using various types of correlation functions, and that the performance of CBHM
is robust with respect to the choice of distance measure and correlation function if the prior is chosen carefully. For
the real-world application of CBHM, however, we recommend to use the B distance function along with exponential
correlation function given the easy implementation.
D.2. An instruction for the implementation of CBHM in a general trial setting
D.2.1 Data preprocessing
Before applying the CBHM model, some adjustments to the data are potentially needed to ensure that the between-
indication distance matrix is invertible. For example, if there are two indications that have equal sample response
rates, the induced distance matrix will be singular. To solve this problem, we add a small value, ε, to the number of
responders for one indication. In a more general case where k > 2 indications have equal sample response rates, we
redefine the corresponding ris as {ri+i, i = 1, 2, . . . , k} to make the response rates distinguishable from each other.
Note that the value of ε can be adjusted according to the total number of indications, I, and the difference between
the null response rate, q0, and the target response rate, q1. In our simulation studies, we set ε = 3(q1 − q0)/I.
D.2.2 Prior specification
Previously in Section D.1, we discussed how to specify the prior for CBHM assuming different distance measures
and correlation functions. In the following instruction for the prior specification of CBHM, we propose to use the
B distance along with the exponential correlation function because of the promising model performance it leads to
and simple procedure required for prior specification.
We first discuss prior specification for the correlation range parameter φ. Following a procedure similar to the
one described in Section D.1, we consider a G(a, 1) prior for φ, and we propose the following algorithm to determine
the value for a, with R code available at https://github.com/Jin93/CBHM:
Algorithm 1: Determining the value of a in the G(a, 1) prior for φ
Input: Input: M , N , q0, q1, α, I, %lb, %ub
Output: Output: a
1 Determine the distance threshold dt:
2 (I) for 1 ≤ i < j ≤ I:
3 under each of the two homogeneous scenarios: (1) pi = q0[i], pj = q0[j], and (2) pi = q1[i],
pj = q1[j], simulate M sample distances between the ith and the jth indications, and denote the
set of sample distances simulated in the two scenarios as {d1,1i,j , . . . , d1,Mi,j , . . . , d2,1i,j , . . . , d2,Mi,j };
(II) calculate the 1− α quantile of {dk,li,j , 1 ≤ i < j ≤ I, k = 1, 2, l = 1, 2, . . . ,M}, which is denoted
as dt.
4 Determine the lower and upper bound of a:
alb = − log(%ub)/dt,
aub = − log(%lb)/dt.
5 Generate a from Unif(alb, aub).
Here M denotes the number of simulations in each of the two homogeneous scenarios, N denotes the vector
of the number of patients enrolled in each indication group, q0 and q1 denote the vector of the null response rates
and target response rates, respectively, for the I indications in the trial, %lb and %ub denote the lower bound and
upper bound, respectively, for the correlation threshold %. A recommended set of input is: M = 5000, α = 0.05,
%lb = 0.3, and %ub = 0.5.
We recommend the following set of priors for θ0, σ2, τ2 and σ20 :
θ0 ∼ N(µ0, σ20), σ2 ∼ IG(cσ2 , dσ2), τ2 ∼ IG(cτ2 , dτ2), σ20 ∼ IG(cσ20 , dσ20 ),
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where the hyperparameters are set to:
µ0 = log
∑K
i=1 q0,i+
∑K
i=1 q1,i
2K
1−
∑K
i=1 q0+
∑K
i=1 q1
2K
,
cτ2 = dτ2 = cσ2 = dσ2 = 0.01, cσ20 = dσ20 = 0.1.
Step 3: Trial process
In a general trial setting, we propose a modified version of the proposed two-stage design in Section 2.3.3 of the
main manuscript, where we simply change q0 and q1 used in the interim analysis and final decision to q0,i’s and
q1,i’s, respectively. The trial design is as follows:
Step 1: at stage one, enroll n1i patients for the ith indication group and collect data D1 = {n1i , Y 1ij , i =
1, . . . , I, j = 1, . . . , n1i }, where n1i denotes the sample size of the ith indication group in stage one.
Step 2: at the end of stage one, apply the CBHM model to data D1 and conduct interim analysis for each
indication i: if Pr(pi > (q0,i + q1,i)/2|D1) < Qf , then stop the enrollment early and conclude that the ith
indication is not sensitive to the treatment; otherwise, continue to stage two until a total of ni patients are
enrolled during the trial. We denote the final data as D = {ni, Yij , i : n2i > 0, j = 1, . . . , ni}.
Step 3: at the end of the trial, assess treatment efficacy on the indications that proceeded to stage two.
Take the ith indication group as an example: if Pr(pi > q0,i|D) > Q, then conclude that the ith indication
is sensitive to the treatment; otherwise, conclude that the ith indication is insensitive.
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